No Easy Answers in Allocating Unapproved COVID-19 Drugs Outside Clinical Trials

Am J Bioeth. 2020 Sep;20(9):W1-W4. doi: 10.1080/15265161.2020.1805525.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Betacoronavirus
  • Biomedical Research
  • COVID-19
  • COVID-19 Drug Treatment
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / virology
  • Decision Making
  • Drug Approval*
  • Health Care Rationing*
  • Humans
  • Pandemics
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / virology
  • Prior Authorization
  • SARS-CoV-2
  • United States